BioCryst Pharmaceuticals Valuation
| BCRX Stock | USD 7.60 0.11 1.47% |
At this time, the firm appears to be undervalued. BioCryst Pharmaceuticals shows a prevailing Real Value of $9.53 per share. The current price of the firm is $7.6. Our model approximates the value of BioCryst Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -19.25, current valuation of 2.05 B, and Profit Margin of (0.30) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BioCryst Pharmaceuticals' valuation include:
Price Book 56.5858 | Enterprise Value 2.1 B | Enterprise Value Ebitda (12.20) | Price Sales 3.8155 | Enterprise Value Revenue 4.9768 |
Undervalued
Today
Please note that BioCryst Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of BioCryst Pharmaceuticals is based on 3 months time horizon. Increasing BioCryst Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioCryst Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioCryst Stock. However, BioCryst Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.6 | Real 9.53 | Target 15.2 | Hype 7.58 | Naive 7.45 |
The intrinsic value of BioCryst Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioCryst Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioCryst Pharmaceuticals helps investors to forecast how BioCryst stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioCryst Pharmaceuticals more accurately as focusing exclusively on BioCryst Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BioCryst Pharmaceuticals' intrinsic value based on its ongoing forecasts of BioCryst Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BioCryst Pharmaceuticals' closest peers.
BioCryst Pharmaceuticals Cash |
|
BioCryst Valuation Trend
Analysing the historical paterns of BioCryst Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of BioCryst Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
BioCryst Revenue by Product
BioCryst Pharmaceuticals Total Value Analysis
BioCryst Pharmaceuticals is currently projected to have valuation of 2.05 B with market capitalization of 1.57 B, debt of 848.71 M, and cash on hands of 417.48 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BioCryst Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.05 B | 1.57 B | 848.71 M | 417.48 M |
BioCryst Pharmaceuticals Investor Information
About 86.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.61. BioCryst Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to BioCryst Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, BioCryst Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.BioCryst Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioCryst Pharmaceuticals has an asset utilization ratio of 64.11 percent. This suggests that the Company is making $0.64 for each dollar of assets. An increasing asset utilization means that BioCryst Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.BioCryst Pharmaceuticals Ownership Allocation
BioCryst Pharmaceuticals holds a total of 207.13 Million outstanding shares. The majority of BioCryst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BioCryst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BioCryst Pharmaceuticals. Please pay attention to any change in the institutional holdings of BioCryst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BioCryst Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 331.41 M. Net Loss for the year was (226.54 M) with profit before overhead, payroll, taxes, and interest of 10.94 M.About BioCryst Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of BioCryst Pharmaceuticals. We calculate exposure to BioCryst Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioCryst Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 326.8 M | 343.1 M | |
| Pretax Profit Margin | (0.68) | (0.72) | |
| Operating Profit Margin | (0.31) | (0.33) | |
| Net Loss | (0.68) | (0.72) | |
| Gross Profit Margin | 0.99 | 1.04 |
BioCryst Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 192.2 M |
BioCryst Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of BioCryst Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioCryst we look at many different elements of the entity such as BioCryst's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioCryst Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioCryst Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioCryst Pharmaceuticals' worth.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.